◆ 会议时间：2023年10月1日至4日
◆ 会议地点：美国 圣迭戈


◆ 会议简介：

2023年第65届美国放射肿瘤学会(ASTRO)年会将于2023年10月1日至4日在美国圣迭戈举行。ASTRO年会（美国放疗年会）是世界放射肿瘤学界最重要的年度会议，每年都会吸引超过10,000名来自世界各地的相关专业人士前来参会。

美国放射肿瘤学会（ASTRO）成立于1958年，是世界上首屈一指的放射肿瘤学组织。ASTRO现拥有超过10000名会员，包括医生、护士、生物学家、物理学家、放疗技师、剂量师和其他专业从事放谢治疗的医疗保健专业人员。 作为领先的放射肿瘤学组织，ASTRO致力于通过专业的教育和培训，支持临床实践和卫生政策标准，促进科学研究和宣传宣等手段改善对患者的护理。——未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

ASTRO 2023 - 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO)
Date: October 1 - 4, 2023
Venue: San Diego Convention Center, San Diego, California, USA

ASTRO2023 摘要征文投稿：

Abstracts

Deadline for New Submissions: Monday, February 13, 2023 at 11:59 PM Pacific Time

点此提交摘要>>>Submit Abstract>>>

点此查看更多摘要提交信息>>>

1. The late-breaking abstract submission site will open on June 26, 2023, and close July 12, 2023.
2. A late-breaking abstract is an original research abstract containing important late-breaking research results that were not available prior to the regular abstract submission deadline. The research is limited to highly significant and timely findings and cannot be a revision of an abstract submitted prior to the regular submission deadline. Trials in progress are not eligible to be submitted as late-breaking abstracts.
3. Late-breaking abstracts must not have been submitted, presented, accepted for presentation or published in any other scientific venue.
4. A special panel of peer reviewers will review the late-breaking abstracts and the corresponding author will be notified of the abstract status by the end of July 2023.

Eligibility

1. Sponsorship or ASTRO membership is not required to submit an abstract.
2. Abstracts must be received by 11:59 p.m. Pacific time, Monday, February 13, 2023.
3. All studies in oncology, radiation oncology and radiation therapy for non-oncologic conditions are eligible for submission. This includes basic and translational science, technology-related, health services research, epidemiologic, patient-focused clinical studies and all phases of trials.
4. An abstract may only be submitted once. Abstracts of clinically-related subjects should be combined into a single abstract. Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
5. Submit new research. Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Submission Requirements

1. Abstract Title: The abstract title should not include results. All titles should be written in title case, and should not include a period at the end.
2. Abstract Body:
   • Abstracts must be properly formatted and organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
   • Abstracts should include a scientific hypothesis in the Purpose/Objectives section, and implications for research, policy or practice in the Conclusions section, when applicable.
   • The abstract cannot contain illustrations, images or graphs. If the abstract is accepted, presenters may include these items in their on-site presentations.
   • An abstract may contain one small table. 
   • The maximum character limit, including the title and body of the abstract and any text in a table, is 2,600 characters. Spaces are not counted.
   • Institution names should not be included in the title or body of the abstract. Alternative language is “at one institution” or “a multi-institution” study, etc. This does not apply to cooperative research group names. 
3. Abstract Authors:
   • A maximum of 20 authors’ names may be listed on each abstract. There are no exceptions. 
   • A Conflict of Interest Disclosure form must be submitted for each author. You can collect this information from the authors before you begin the submission using this form.
   • The principal investigator (PI) should be listed as the final author on the abstract.
   • There is no mechanism for listing co-lead authors or co-PI’s.
   • Each author must have made substantial contributions to:
     • conception and design, or analysis and interpretation of data, and
     • drafting the abstract or revising it critically for important intellectual content, and
     • final approval of the version to be submitted/published.
4. Use of Brand Names and Trade Names: Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract. ASTRO reserves the right to replace proprietary names with generic names.
5. Track: The most appropriate track and subcategory for the abstract should be selected. Please note that the AM Scientific Committee Chairs have the authority to recategorize any abstract.
6. 提交费 Submission Fee: A $75 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Payment must be rendered using a credit card. 

Trials in Progress, Interim Analysis and Database Studies

Trials in Progress
Trials in Progress provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. Trials in Progress will be considered for digital poster only.

Please ensure that the Trial in Progress meets the following criteria before submitting the abstract:

1. All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a Trials in Progress submission.
2. Trials submitted are ongoing and have not reached pre-specified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
3. Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (there are no exceptions to this criterion). It is acceptable if the trial has not enrolled its first patient yet.
4. Clinical trial registry number is required.

When submitting a Trial in Progress, be sure to check the appropriate box on the Title step of the submission process. Please also select Trial in Progress as the subcategory on the Track step.

Interim Analysis
In general, ASTRO does not accept abstracts reporting an interim analysis that is intended to evaluate experimental treatment regimen(s) with respect to efficacy or safety at any time prior to formal completion of a trial.

Abstracts reporting trial process updates, such as accrual, baseline characteristics and non-protocol specific safety information, will be considered for posters only for promotional purposes.

Database Studies
Retrospective registry databases, such as National Cancer Database (NCDB), Surveillance, Epidemiology and End Results (SEER), etc., are valuable resources for patterns of care assessment, and may generate important evidence for comparative effectiveness research.

For comparative effectiveness reports, prioritization will be given to those when the level 1 evidence from randomized trials is obsolete or difficult to obtain. Abstracts should include brief descriptions on statistical methods and justifications, such as the choice of statistical significance level, effect size, methods for confounding adjustment, etc., to facilitate proper interpretations.

重要日期

ASTRO 2023年美国放疗年会-ASTRO放射治疗肿瘤年会-ASTRO放射年会-美国放射肿瘤学年会

◆ 参会对象：
放射科医师，肿瘤科医师，护士，生物学家，物理学家，放疗技师，放射剂量师，药疗企业代表，以及其他相关卫生保健专业人士等等。